<SEC-DOCUMENT>0000950170-25-088486.txt : 20250620
<SEC-HEADER>0000950170-25-088486.hdr.sgml : 20250620
<ACCEPTANCE-DATETIME>20250620160406
ACCESSION NUMBER:		0000950170-25-088486
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250617
FILED AS OF DATE:		20250620
DATE AS OF CHANGE:		20250620

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Miller-Rich Nancy
		CENTRAL INDEX KEY:			0001735084
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39782
		FILM NUMBER:		251061274

	MAIL ADDRESS:	
		STREET 1:		C/O INTERCEPT PHARMACEUTICALS, INC.
		STREET 2:		10 HUDSON YARDS, 37TH FL
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			4D Molecular Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001650648
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				473506994
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5105052680

	MAIL ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	4D Molecular Therapeutics Inc.
		DATE OF NAME CHANGE:	20200506

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	4D Molecular Therapeutics Inc
		DATE OF NAME CHANGE:	20150811
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-06-17</periodOfReport>

    <issuer>
        <issuerCik>0001650648</issuerCik>
        <issuerName>4D Molecular Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>FDMT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001735084</rptOwnerCik>
            <rptOwnerName>Miller-Rich Nancy</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O 4D MOLECULAR THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>5858 HORTON STREET #455</rptOwnerStreet2>
            <rptOwnerCity>EMERYVILLE</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94608</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>4.15</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-06-17</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>22500</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-06-16</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>22500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>22500</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Automatically granted pursuant to the terms of the Company's non-employee director compensation program.</footnote>
        <footnote id="F2">The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Scott Bizily as Attorney-in-Fact for Nancy Miller-Rich</signatureName>
        <signatureDate>2025-06-20</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
